Pepper Bio has licensed rights to lerociclib, a molecule that G1 Therapeutics designed to offer dosing and safety advantages over approved therapies in the same drug class. EQRx previously held rights to the drug, but returned them after the company was acquired last year.
AstraZeneca drug Imjudo is now FDA approved for treating advanced liver cancer. The infused therapy is administered under a novel dosing schedule in addition to Imfinzi, an AstraZeneca drug already approved for treating several different types of cancer.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Taiho Oncology’s cancer drug Lytgobi is the third FDA-approved therapy for bile duct cancer driven by FGFR2 genetic alterations. The accelerated approval for Taiho’s drug follows regulatory nods for products from Incyte and QED Therapeutics that address the same genetic signature.
Omega Therapeutics has raised more than $210 million in the past eight months for R&D of medicines that regulate genes. The company’s lead therapeutic candidate addresses a validated but elusive cancer target.
The company said it had shared data from the Phase III study with the FDA. However, per FDA regulations, there is a risk that the accelerated approval for hepatocellular carcinoma could be withdrawn.
Surefire Medical gets financing to spread the use of its device systems designed for chemoembolization and radioembolization procedures in treating both primary and secondary (metastatic) liver cancer.
As technology advances, AI-powered tools will increasingly reduce the administrative burdens on healthcare providers.